肿瘤细胞治疗研究
英文原题：CAR-T therapy in non-small cell lung cancer: Clinical prospects, potential, and strategies for cardiotoxicity management.
肺癌的发病率居所有恶性肿瘤首位，目前的治疗策略包括手术、化疗、免疫治疗和靶向治疗。
肺癌在所有恶性肿瘤中发病率居首，当前治疗策略包括手术、化疗、免疫治疗和靶向治疗。尽管取得进展，晚期非小细胞肺癌（NSCLC）的耐药仍是主要障碍，亟需创新治疗方法。CAR-T 细胞疗法治疗血液癌症已显示出令人瞩目且持久的疗效，但用于肺癌等实体瘤仍受限。本综述总结CAR-T治疗NSCLC的近期进展和未来方向，重点介绍EGFR、MSLN、PD-L1、MUC1、CEA和ROR1等主要治疗靶点，并探讨CAR-T与其他治疗方式联用的疗效和潜力。此外，文章讨论NSCLC患者CAR-T治疗的不良事件，重点关注细胞因子释放综合征（CRS）和心血管并发症，包括其发生率、病理生理学、相互关系及管理策略。
Lung cancer ranks first among all malignancies in incidence, with current treatment strategies including surgery, chemotherapy, immunotherapy, and targeted therapy. Despite these advances, drug resistance in advanced non-small cell lung cancer (NSCLC) remains a major obstacle and innovative therapeutic approaches are imperative to address it. Chimeric antigen receptor T-cell (CAR-T) therapy has shown impressive and long-lasting results in blood cancers, but its success in solid tumors such as lung cancer remains limited. This review summarizes recent advances and future directions of CAR-T therapy in NSCLC, focusing on major therapeutic targets such as EGFR, MSLN, PD-L1, MUC1, CEA, and ROR1, as well as on the efficacy and potential of combining CAR-T therapy with other treatment modalities. Additionally, we discuss adverse events in NSCLC patients undergoing CAR-T therapy, emphasizing cytokine release syndrome (CRS) and cardiovascular complications-their incidence, pathophysiology, interrelation, and management strategies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
